Embryonic thymic subcluster representation following carrier or drug administration
| Cell subclusters . | Number and percent of cells/sample . | Putative cell type (Identifier genes) . | |||
|---|---|---|---|---|---|
| Tbx1+/+ (carrier) (11,820) . | Tbx1neo2/neo2 (carrier) (11,123) . | Tbx1neo2/neo2 (minoxidil) (3,293) . | Tbx1neo2/neo2 (PGE2) (4,290) . | ||
| Mesenchymal | 2,820 | 6,400 | 998 | 882 | Mesenchymal subcluster (genes) |
| M-1 | 1,048 (37%) | 3,748 (59%)a | 426 (43%) | 396 (44%) | Caps Fb 2b (Adamts2, Bgn, and Fbn1) and 3 (Igf1, Dcn, and Olfml3) |
| M-2 | 797 (28%) | 432 (7%)b | 244 (24%) | 229 (25%) | Pericytes-A (Ebf1, Kcnj8, Pdgfrb, and Cspg4)—high |
| M-3 | 671 (24%) | 1,304 (20%) | 253 (25%) | 219 (26%) | Pericytes-B (Ebf1, Kcnj8, Pdgfrb, and Cspg4)—low. Proliferating cells (Mki67 and Top2a1) |
| M-4 | 247 (9%) | 59 (1%)b | 61 (6%) | 22 (2.5%) | Cap Fb 1 (Adh1a2, Capn6, Itm2a, and Svep1) |
| M-5 | 15 (0.5%) | 583 (9%)a | 2 (0.2%) | 3 (0.3%) | Cap Fb (Sox 9) In Tbx1neo2/neo2 thymuses: Chondrocytes (Sox 5,6,9, Col2a1 Col9a1, Col11a1, and Acan) |
| M-6 | 42 (1.5%) | 274 (4%) | 12 (1.2%) | 13 (1.5%) | Thymic mesoderm-derived mesenchymal subset with transient myogenic potential (Chrna1, Pax7, Myod1, Myog, Pdgfra, Vcam1, and Col1a2) and some neural crest-derived cells (Sox10 and Foxd3) |
| Endothelial | 216 | 261 | 109 | 104 | Endothelial (Cdh1 and Pecam1) |
| Epithelial | 3,666 | 1,354 | 1,004 | 1,318 | Epithelial subcluster (genes) |
| E-1 | 1,692 (46%) | 660 (49%) | 526 (52%) | 685 (52%) | cTEClo I (EpCAM, Krt8, low levels of Psmb11, Prss16, and Ccl25) |
| E-2 | 179 (5%) | 36 (3%) | 18 (2%) | 19 (1%) | cTEC lo II (EpCAM, Krt8, low levels of Psmb11, Prss16, and Ccl25) |
| E-3 | 1,032 (28%) | 390 (29%) | 267 (27%) | 343 (26%) | cTEChi (EpCAM, Krt8, Psmb11, Prss16, and Ccl25) |
| E-4 | 662 (18%) | 260 (19%) | 193 (19%) | 270 (20%) | Bipotent thymic epithelial progenitor population (EpCAM, Krt8, Krt14, Krt5, Krtdap, Cldn4, lower levels of MHC class II, and Ccl21) |
| E-5 | 101 (3%) | 8 (0.6%) | 0 (0%)c | 1 (0.8%) | Immature TECs; Pth marker (EpCAM, Krt8, Pth, and Chga) |
| Hematopoietic | 4,480 | 1,308 | 796 | 1,275 | Hematopoietic subclusters |
| H-1 | 842 (19%) | 381 (24%) | 351 (44%) | 637 (50%) | DN3 (high levels Ptprc, Lck, Cd3g, Runx1, and Il2ra) |
| H-2 | 197 (4%) | 314 (24%)a | 96 (12%) | 76 (6%) | Macrophages and dendritic cells (Pf4, CD68, Fcgr3, and C1qa) |
| H-3 | 1,224 (27%) | 431 (29%) | 301 (38%) | 486 (38%) | Early TP and DN2 (Cd7, Cd25, Il2ra, and CD44) |
| H-4 | 2,217 (49%) | 182 (14%) | 48 (6%) | 76 (6%) | DN4/innate-like cytotoxic T/NK precursors (Ifitm1, Ifitm2, Gzma, and Plac8) |
| Cell subclusters . | Number and percent of cells/sample . | Putative cell type (Identifier genes) . | |||
|---|---|---|---|---|---|
| Tbx1+/+ (carrier) (11,820) . | Tbx1neo2/neo2 (carrier) (11,123) . | Tbx1neo2/neo2 (minoxidil) (3,293) . | Tbx1neo2/neo2 (PGE2) (4,290) . | ||
| Mesenchymal | 2,820 | 6,400 | 998 | 882 | Mesenchymal subcluster (genes) |
| M-1 | 1,048 (37%) | 3,748 (59%)a | 426 (43%) | 396 (44%) | Caps Fb 2b (Adamts2, Bgn, and Fbn1) and 3 (Igf1, Dcn, and Olfml3) |
| M-2 | 797 (28%) | 432 (7%)b | 244 (24%) | 229 (25%) | Pericytes-A (Ebf1, Kcnj8, Pdgfrb, and Cspg4)—high |
| M-3 | 671 (24%) | 1,304 (20%) | 253 (25%) | 219 (26%) | Pericytes-B (Ebf1, Kcnj8, Pdgfrb, and Cspg4)—low. Proliferating cells (Mki67 and Top2a1) |
| M-4 | 247 (9%) | 59 (1%)b | 61 (6%) | 22 (2.5%) | Cap Fb 1 (Adh1a2, Capn6, Itm2a, and Svep1) |
| M-5 | 15 (0.5%) | 583 (9%)a | 2 (0.2%) | 3 (0.3%) | Cap Fb (Sox 9) In Tbx1neo2/neo2 thymuses: Chondrocytes (Sox 5,6,9, Col2a1 Col9a1, Col11a1, and Acan) |
| M-6 | 42 (1.5%) | 274 (4%) | 12 (1.2%) | 13 (1.5%) | Thymic mesoderm-derived mesenchymal subset with transient myogenic potential (Chrna1, Pax7, Myod1, Myog, Pdgfra, Vcam1, and Col1a2) and some neural crest-derived cells (Sox10 and Foxd3) |
| Endothelial | 216 | 261 | 109 | 104 | Endothelial (Cdh1 and Pecam1) |
| Epithelial | 3,666 | 1,354 | 1,004 | 1,318 | Epithelial subcluster (genes) |
| E-1 | 1,692 (46%) | 660 (49%) | 526 (52%) | 685 (52%) | cTEClo I (EpCAM, Krt8, low levels of Psmb11, Prss16, and Ccl25) |
| E-2 | 179 (5%) | 36 (3%) | 18 (2%) | 19 (1%) | cTEC lo II (EpCAM, Krt8, low levels of Psmb11, Prss16, and Ccl25) |
| E-3 | 1,032 (28%) | 390 (29%) | 267 (27%) | 343 (26%) | cTEChi (EpCAM, Krt8, Psmb11, Prss16, and Ccl25) |
| E-4 | 662 (18%) | 260 (19%) | 193 (19%) | 270 (20%) | Bipotent thymic epithelial progenitor population (EpCAM, Krt8, Krt14, Krt5, Krtdap, Cldn4, lower levels of MHC class II, and Ccl21) |
| E-5 | 101 (3%) | 8 (0.6%) | 0 (0%)c | 1 (0.8%) | Immature TECs; Pth marker (EpCAM, Krt8, Pth, and Chga) |
| Hematopoietic | 4,480 | 1,308 | 796 | 1,275 | Hematopoietic subclusters |
| H-1 | 842 (19%) | 381 (24%) | 351 (44%) | 637 (50%) | DN3 (high levels Ptprc, Lck, Cd3g, Runx1, and Il2ra) |
| H-2 | 197 (4%) | 314 (24%)a | 96 (12%) | 76 (6%) | Macrophages and dendritic cells (Pf4, CD68, Fcgr3, and C1qa) |
| H-3 | 1,224 (27%) | 431 (29%) | 301 (38%) | 486 (38%) | Early TP and DN2 (Cd7, Cd25, Il2ra, and CD44) |
| H-4 | 2,217 (49%) | 182 (14%) | 48 (6%) | 76 (6%) | DN4/innate-like cytotoxic T/NK precursors (Ifitm1, Ifitm2, Gzma, and Plac8) |